Get your patients started with ORLADEYOTM (berotralstat)

Switching patients should be based on their clinical condition and your discretion1

These recommendations are from the manufacturer of ORLADEYO and have not been evaluated in a controlled clinical study.

ORLADEYO™ switch considerations summary for HCPs ORLADEYO™ switch considerations summary for HCPs

Dosing recommendations

  • The recommended dosage of ORLADEYO is one 150 mg capsule taken orally once daily with food2
    • For certain patient populations, the recommended dosage is one 110 mg capsule taken orally once daily with food2

Other considerations

  • Ensure patients have rescue therapy available for treatment of breakthrough hereditary angioedema (HAE) attacks2
  • Patients should not take additional doses of ORLADEYO to treat an acute attack of HAE; the safety and effectiveness of ORLADEYO as a rescue treatment for HAE attacks have not been established2
  • GI reactions may occur in patients receiving ORLADEYO. If GI reactions persist, a reduced dosage of 110 mg once daily with food may be considered2